GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bioray Biotech Co Ltd (ROCO:7561) » Definitions » EV-to-EBIT

Bioray Biotech Co (ROCO:7561) EV-to-EBIT : -58.79 (As of Jun. 23, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Bioray Biotech Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bioray Biotech Co's Enterprise Value is NT$756.5 Mil. Bioray Biotech Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-12.9 Mil. Therefore, Bioray Biotech Co's EV-to-EBIT for today is -58.79.

The historical rank and industry rank for Bioray Biotech Co's EV-to-EBIT or its related term are showing as below:

ROCO:7561' s EV-to-EBIT Range Over the Past 10 Years
Min: -4477.76   Med: -134.82   Max: 459.98
Current: -58.79

During the past 7 years, the highest EV-to-EBIT of Bioray Biotech Co was 459.98. The lowest was -4477.76. And the median was -134.82.

ROCO:7561's EV-to-EBIT is ranked worse than
100% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.05 vs ROCO:7561: -58.79

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Bioray Biotech Co's Enterprise Value for the quarter that ended in Dec. 2023 was NT$881.3 Mil. Bioray Biotech Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-12.9 Mil. Bioray Biotech Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -1.46%.


Bioray Biotech Co EV-to-EBIT Historical Data

The historical data trend for Bioray Biotech Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioray Biotech Co EV-to-EBIT Chart

Bioray Biotech Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial - -2,648.05 -231.95 421.75 -68.49

Bioray Biotech Co Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -231.95 - 421.75 - -68.49

Competitive Comparison of Bioray Biotech Co's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Bioray Biotech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioray Biotech Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bioray Biotech Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bioray Biotech Co's EV-to-EBIT falls into.



Bioray Biotech Co EV-to-EBIT Calculation

Bioray Biotech Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=756.482/-12.868
=-58.79

Bioray Biotech Co's current Enterprise Value is NT$756.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bioray Biotech Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-12.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioray Biotech Co  (ROCO:7561) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Bioray Biotech Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-12.868/881.335
=-1.46 %

Bioray Biotech Co's Enterprise Value for the quarter that ended in Dec. 2023 was NT$881.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bioray Biotech Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-12.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioray Biotech Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Bioray Biotech Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioray Biotech Co (ROCO:7561) Business Description

Traded in Other Exchanges
N/A
Address
No. 21-3, Shennong East Road, Changzhi Township, Pingtung County, Pingtung City, TWN, 90846
Bioray Biotech Co Ltd is engaged in the development and manufacturing of biological agents, including functional probiotics, medicinal fungi, and immune cell preparations. The company provides capsules, powders, lozenges, and liquids for Skincare, Anti-aging and anti-inflammatory, Silver Hair Maintenance, and Microbe and mineral supplement among others.

Bioray Biotech Co (ROCO:7561) Headlines

No Headlines